Breaking News

J&J To Acquire Cougar Biotechnology

Johnson & Johnson and Cougar Biotechnology, Inc. entered a definitive agreement under which J&J will acquire Cougar Biotechnology for approximately $1.0 billion in cash.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Johnson & Johnson and Cougar Biotechnology, Inc. entered a definitive agreement under which J&J will acquire Cougar Biotechnology for approximately $1.0 billion in cash. Cougar Biotechnology, a development stage biopharmaceutical company with an oncology focus, has compounds in development for the treatment of prostate cancer, breast cancer and multiple myeloma. The company will work with J&J’s Ortho Biotech Oncology R&D, a unit of Centocor R&D, Inc. Cougar Biotec...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters